9-May-17
Quote of the Day : "All there is to investing is picking good stocks at good times and staying with them as
long as they remain good companies. " Warren Buffett
Narnolia Securities Ltd
IEA Snapshot
Top News
EMAMILTD Q4FY17 result concall update: Concall Highlights 4QFY17 VISAKA Indusries Ltd.
International business: degrew by 38% in Q4FY17 due to >>Building Products contribute handsomely (36% YoY).
inventory correction and pressure in MENA region. >>Spinning unit was under pressure due to increase in Operating and
Worse is over for international business. Expects double digit administrative expenses & due to Depreciation and interest cost incurred
growth from international business in FY18. during the year due to capacity expansion project which went into
Domestic volume declined by 1.5% whereas value growth production in Nov 1, 2016. Just when it gets commercialised,
remained 3% in Q4FY17. Demonetization happened which affected the existing production also.
Domestic business is still subdued. Volatility in oil prices also impacted.
Company is taking major distribution restructuring. Increased >>Expect doing well in FY18.
direct reach by 90000 outlets in Q4FY17. >>Cement volumes were fairly good.
Commissioned Assam Plant (invested Rs 300cr)in >>Working capital days reduces to 11 days.
Q4FY17.Fiscal benefits of this plant with go for 10 years. >>Free cash flow is expected to increase from last year.
Overall Tax rate: next five years could be under MAT rate. >>Total debt in BS is 250 Cr. Inventory & receivable will clear the debt. No
Gross margin: Maintain Gross margin in FY18, max. can be debt is depending on CF.
impacted by 20 bps. >>Expected Volume growth 6% in FY18.
AD&P expenses: will go up by 1% and .5% in FY18. Natco Pharma has launched generic sofosbuvir 400 mg/velpatasvir 100
Product launches: Launched whole range of pain reliever mg tablets used for the treatment of chronic hepatitis C in India. The
under Jhandu brand (spray, roll on and gel). company has launched a generic version of sofosbuvir 400 mg/velpatasvir
Planning to launch many more products in 2HFY18. 100 mg fixed dose combination in India under the brand name Velpanat
Company will try to reduce impact of direct reach expansion
cost by reducing other expenses items. Wockhardt is seeking shareholders' approval via a postal ballot for
If indirect tax related Ayurvedic products remains 12% and raising additional capital by way of one or more public or private offerings,
personal care products remained 18% than company will including through qualified institutional placement (QIP), for an amount
marginally benefited. Presently company pays 11-11.5% not exceeding Rs. 1,000 crore
indirect tax for Ayurvedic products and 24% for personal care
products. Torrent Pharma has completed the acquisition of women healthcare
Capex.: Rs150 cr for FY18,plans to pay debt by March2018. brands Regestrone and Pregachieve for India from Swiss pharma major
Modern trade grew by 20% in Q4FY17 and FY17. Novartis AG. While the company did not disclose the deal size, it is
estimated to be close to Rs 500 crore.
Narnolia Securities Ltd
F&O OPEN INTEREST ( Number of Contracts )
Individual Foreign Institutions
TRADING IDEAS
Result Q4FY17
BSE Code NSE CODE SALES SALES YoY PAT PAT YoY
524330 JAYAGROGN 424 14 15.60 95.00
532345 GATI 414 (2) 9.30 (40.15)
500680 PFIZER 453 (11) 68.00 (22.05)
500250 LGBBROSLTD 313 19 17.00 8.56
532698 NITINSPIN 285 50 15.70 38.08
507815 GILLETTE 534 (3) 105.80 30.86
524669 HESTERBIO 35 28 7.08 28.40
509715 JAYSREETEA 131 (1) (41.79) 23.93
500730 NOCIL 193 10 25.46 13.00
523539 PRECWIRE 250 19 6.92 39.52
532144 WELCORP 2172 21 30.39 31.84
500002 ABB 2318 17 91.84 29.39
534816 INFRATEL 1606 13 600.50 (16.41)
532483 Canbk 2374 14 (3905.00)
532477 Unionbank 2387 0 108.00 0.13
Economic Calendar
Monday Tuesday Wednesday Thursday Friday
Country
8th May 17 9th May 17 10th May 17 11th May 17 12th May 17
Risk Disclosure & Disclaimer: This report/message is for the personal information of
the authorized recipient and does not construe to be any investment, legal or taxation
advice to you. Narnolia Securities Ltd. (Hereinafter referred as NSL) is not soliciting any
action based upon it. This report/message is not for public distribution and has been
furnished to you solely for your information and should not be reproduced or
redistributed to any other person in any from. The report/message is based upon publicly
available information, findings of our research wing East wind & information that we
consider reliable, but we do not represent that it is accurate or complete and we do not
provide any express or implied warranty of any kind, and also these are subject to change
without notice. The recipients of this report should rely on their own investigations,
should use their own judgment for taking any investment decisions keeping in mind that
past performance is not necessarily a guide to future performance & that the the value of
any investment or income are subject to market and other risks. Further it will be safe to
assume that NSL and /or its Group or associate Companies, their Directors, affiliates
and/or employees may have interests/ positions, financial or otherwise, individually or
otherwise in the recommended/mentioned securities/mutual funds/ model funds and
other investment products which may be added or disposed including & other mentioned
in this report/message.